Raloxifene
- Generic Name
- Raloxifene
- Brand Names
- Evista, Optruma, Raloxifene Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C28H27NO4S
- CAS Number
- 84449-90-1
- Unique Ingredient Identifier
- YX9162EO3I
- Background
Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation. Exhibiting tissue-specific effects distinct from estradiol, raloxifene is the first of the benzothiophene group of antiestrogens to be labe...
- Indication
Indicated for the prevention and treatment of osteoporosis in postmenopausal women, as well as prevention and treatment of corticosteroid-induced bone loss.
Indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or postmenopausal women with a high risk for invasive breast cancer.
- Associated Conditions
- Invasive Breast Cancer, Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment
- Associated Therapies
- -
Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Dompé Farmaceutici S.p.A
- Target Recruit Count
- 61
- Registration Number
- NCT05172050
- Locations
- 🇫🇷
CHU Amiens, Amiens, France
🇫🇷CH Emile Roux le Puy en Velay, Le Puy-en-Velay, France
🇫🇷Centre Hospitalier de Troyes, Troyes, France
Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 18028
- Registration Number
- NCT04736693
- Locations
- 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
- Conditions
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 51
- Registration Number
- NCT03623633
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Adjunctive Selective Estrogen Receptor Modulators on Negative and Cognitive Symptoms of Schizophrenia in Women
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 45
- Registration Number
- NCT03418831
- Locations
- 🇨🇳
CHINA, Shanghai, Minhang, China
Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT03147196
Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder
- Conditions
- Interventions
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Iris Sommer
- Target Recruit Count
- 110
- Registration Number
- NCT03043820
- Locations
- 🇳🇱
UMC Utrecht, Utrecht, Netherlands
DP-R213 Phase 1 Pharmacokinetics Study
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Alvogen Korea
- Target Recruit Count
- 46
- Registration Number
- NCT03010267
Osteoporosis Treatment in Post-menopausal Women
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- Taichung Veterans General Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT03006003
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
🇨🇳outpatient clinic of the Division of Endocrinology and Metabolism in Taichung Veterans General Hospital, Taichung, Taiwan
Clinical Trial on the Efficacy of Raloxifene on Disease Activity in Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Sara Saeidi Shahri
- Target Recruit Count
- 34
- Registration Number
- NCT02982083
The Effects of Seasonal Changes in Osteoporosis Treatment
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Toshihiko Kono
- Target Recruit Count
- 200
- Registration Number
- NCT02977949
- Locations
- 🇯🇵
Tomidahama Hospital, Yokkaichi, Mie, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.